Back to Newsroom
Back to Newsroom

Pediapharm to Present at the 7th Annual LD Micro Invitational

Wednesday, 17 May 2017 09:30 AM

Pediapharm Inc.

LOS ANGELES, CA / ACCESSWIRE / May 17, 2017 / Pediapharm Inc. (TSX-V: PDP), Canada's Leading Pediatric Pharmaceutical Company, today announced that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6 at 3:30PM PST / 6:30PM EST. Sylvain Chretien, CEO of Pediapharm Inc., will be giving the presentation and meeting with investors.

Pediapharm's mission is to bring to the Canadian market the latest innovative pediatric products from around the world with the objective to improve the health and the well-being of children in Canada. It has entered into numerous commercial agreements with partners from around the world, including North America and Europe. The Company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; Rupall™, an innovative new allergy medication with a unique dual mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is currently under review with Health Canada.

"This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company's history," stated Chris Lahiji, President of LD Micro. "LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof."

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space.

View Pediapharm's profile here: http://www.ldmicro.com/profile/PDP.V

Profiles powered by LD Micro - News Compliments of Accesswire.

About Pediapharm Inc.

Pediapharm's mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. It has entered into numerous commercial agreements with partners from Canada and other countries around the world. The Company's innovative product portfolio includes NYDA®, a breakthrough treatment for head lice; Rupall™, an innovative new allergy medication with a unique mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for severe drooling, which is under review with Health Canada.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.

Contact:

Name: Roland Boivin
Phone: 514-762-2626 X202
Address: 225 - 1 Place du Commerce, Verdun, QC, Canada, H3E 1A2
Email: [email protected]

Or

Name: Frank Candido
Phone: 514-969-5530
Email: [email protected]

SOURCE: Pediapharm Inc.

Topic:
Conferences
Back to newsroom
Back to Newsroom
Share by: